18 results about "Reduced dose" patented technology

A method of treating an orexin-2 mediated disorder in a human subject in need thereof is provided. The method comprises administering seltorexant or a pharmaceutically acceptable salt or hydrate thereof at a therapeutically effective daily dose to the subject, when the subject does not have a hepatic impairment. The method also comprises administering seltorexant or the pharmaceutically acceptable salt or hydrate thereof at a reduced dose less than the daily dose to the subject, when the subject has moderate hepatic impairment.

The present invention relates to method for medical imaging, the method being characterized in that it comprises the implementation, by a data processor (11b) of a second server (1b), of steps of: (a) Obtaining at least one candidate pre-contrast image and a candidate contrast image respectively depicting a body part prior to and after an injection of a first dose of contrast agent, wherein said first dose is higher than a predetermined low dose, the predetermined reduced dose being lower than a predetermined standard dose; a convolutional neural network, CNN, being trained to reconstruct, from at least a pre-contrast input image and a low dose contrast input image respectively depicting a body part prior to and after an injection of said low dose of contrast agent, a standard dose contrast image depicting said body part after an injection of said standard dose of contrast agent; (b) Simulating an injection of a second dose of contrast agent which is higher than the standard dose, wherein said simulating comprises generating a synthetic contrast image by applying the CNN to the at least one candidate pre-contrast image and the candidate contrast image.

The present disclosure encompasses combinations of ralinepag with a cGMP-elevating agent or prostanoid such as riociguat, treprostinil, or iloprost for treating PAH. The disclosed combination therapy provides for advantages such as improved efficacy, improved safety, reduced doses and / or frequency of ralinepag and / or riociguat, reduced doses and / or frequency of ralinepag and / or treprostinil, and reduced doses and / or frequency of ralinepag and / or iloprost. In some embodiments, the clinical effectiveness of a reduced dose combination is additive or synergistic compared to that provided by the corresponding ralinepag, riociguat, treprostinil, and / or iloprost monotherapies.

Oral dosage forms of metaxalone having improved bioavailability in the fed and fasted states, including dosage forms that employ a reduced dose based on such improved bioavailability.

In one aspect, described herein is a method of treating a relapsed or refractory pediatric low-grade glioma (pLGG) in a subject in need thereof, comprising administering to the subject tovorafenib or a salt thereof, wherein the subject is 6 months of age or older. In some embodiments, the pediatric low-grade glioma (pLGG) harbors a BRAF fusion or rearrangement, or BRAF V600 mutation. In some embodiments, the method comprises administering a starting dose, a reduced dose, and optionally a further reduced dose.

The technology described herein relates to a computerized method and system for generating at least one of a single light indication pattern for a dose detection system via an LED based, for example, on a use case type and a battery life state type. The case types may include pairing, manual synchronization, and / or dose injection, and the battery life state types may include 1 to 3 different states. Another method and system for reducing battery consumption of a dose detection system by monitoring continuous activation of a power-on module and / or alerting a user in a manner to enable the user to take action. At least a portion of the information obtained from these techniques may be communicated to a paired remote electronic device, such as a user's smartphone.

A drug delivery device (100) comprising: a housing (102, 104) including one or more bridge contacts (304); a movable dial (108) at least partially located within the housing and arranged to move relative to the one or more bridge contacts (304), the dial comprising a series of conductive strips (306, 310, 314) on an outer surface of the dial (108), wherein the one or more bridge contacts (304) selectively connect and disconnect with conductive strips (306, 310, 314) in the series of conductive strips (306, 310, 314) when the movable dial (108) moves, thereby providing an alternating electrical signal; at least one electronic component (202, 218) configured to detect the alternating electrical signal, determine whether the electrical signal indicates contact between the conductive strips and the bridge contacts, and determine a dose of a medicament programmed into the drug delivery device based on the electrical signal.

Systems and methods for using a field bounding box to reduce the dose calculation volume in a treatment plan optimization process and thereby reduce the computation effort at each iteration of the optimization process.

A method in which: (a) a patient is positioned in an X-ray device; (b) a 3D scout image with reduced dose and with a predefined volume sizes and a predefined center of rotation is created; (c) on the 3D scout image, a practitioner marks the tooth (d) a software determines, based on the position of the enveloping geometry, the available centers of rotation and calculates, based on reference points of the enveloping geometry, the imaging positions; (e) based on the imaging positions, a center of rotation is selected; (f) the previously determined aperture positions and the detector regions to be irradiated are transmitted; (g) the high-resolution image is reconstructed and the newly acquired high-resolution information is superimposed in the 3D scout image; (h) the practitioner receives the 3D scout image for diagnosis and further use.

The present technology is directed generally to electrical stimulation and associated systems and methods. For example, the present technology provides stimulation schedules / regimens that are expected to reduce the amount of power required for paresthesia-free stimulation, while maintaining the benefits of paresthesia- free stimulation. This is accomplished by reducing the dose of paresthesia-free neurostimulation provided to a patient over time. The dose can be reduced without a corresponding reduction, or significant reduction, in effectiveness.

The present invention relates to a cuttable and consumable tape-type or bar-type preparation containing a pharmacologically active ingredient, and, more specifically, to: a tape-type or bar-type preparation enabling precise drug dose control through tape or bar length; and a method for controlling drug dose through length by using the preparation. The tape-type or bar-type preparation of the present invention has cut lines formed at equal intervals in the longitudinal direction, and contains uniform drug doses according to predetermined lengths, thereby enabling accurate dose measurement customized to the age and the weight of an administration subject (children or adults) and enabling easy cutting by the hands and consumption. That is, in the tape-type or bar-type preparation of the present invention, the length of the tape or bar and the drug dose are proportional to each other so that the length required in administering an appropriate dose according to the age and the weight of an administration subject (children or adults) can be easily measured and cut, and thus errors in dose calculation can be minimized and side effects can be reduced. In addition, the tape-type or bar-type preparation of the present invention is a semi-solid formulation and, unlike a liquid formulation, is easy to hold and be consumed without spillage, has excellent storage stability, and is easy to store and carry.

To provide oral dosage forms of metaxalone having improved bioavailability in the fed and fasted states.SOLUTION: Provided is a solid oral pharmaceutical formulation comprising metaxalone and one or more pharmaceutically acceptable excipients: a. a 640 mg tablet or capsule of the formulation releases at least 50 wt.%, 55 wt.%, 60 wt.%, 65 wt.%, or 70 wt.% of its metaxalone in 60 minutes when tested in 900 mL 0.5% SLS in water in a USP Apparatus Type 2 (paddle) at 100 rpm and 37±0.5°C; and / or b. a 100 mg tablet or capsule of the formulation releases at least 65 wt.%, 70 wt.%, 75 wt.%, or 80 wt.% of its metaxalone in 300 minutes when tested in 900 mL of fasted state simulated intestinal fluid in a USP Apparatus Type 2 (paddle) at 50 rpm and 37±0.5°C.SELECTED DRAWING: Figure 1

A method of treating an orexin-2 mediated condition in a human subject in need thereof is provided. The method comprises administering to the subject a therapeutically effective daily dose of sitorraxen, or a pharmaceutically acceptable salt or hydrate thereof, when the subject is not suffering from liver injury. The method further comprises administering to the subject when the subject is suffering from a moderate liver injury, sitorraxone, or a pharmaceutically acceptable salt or hydrate thereof, in a reduced dose that is lower than the daily dose.

A method for retreatment of a tumor includes the step of providing therapy pulses to the tumor according to a pulse reduced dose rate (PRDR) therapy pattern. The therapy pulse is a PRDR intensity modulated proton therapy (IMPT) pulse, including a proton pulse provided to the tumor. Also disclosed is a system for retreatment of a tumor, the system comprising: a first beamlet emitter for providing a first plurality of intensity modulated proton therapy (IMPT) pulses according to a pulse reduced dose rate (PRDR) therapy pattern; and a second beamlet emitter for providing a second plurality of intensity modulated proton therapy (IMPT) pulses according to the PRNR therapy pattern. The system also includes a controller configured to cause the first plurality of IMPT pulses and the second plurality of IMPT pulses to be provided to the tumor in a pulse sequence with a time gap between delivery of the pulses.

The present disclosure encompasses combinations of ralinepag with a cGMP-elevating agent or prostanoid such as riociguat, treprostinil, or iloprost for treating PAH. The disclosed combination therapy provides for advantages such as improved efficacy, improved safety, reduced doses and / or frequency of ralinepag and / or riociguat, reduced doses and / or frequency of ralinepag and / or treprostinil, and reduced doses and / or frequency of ralinepag and / or iloprost. In some embodiments, the clinical effectiveness of a reduced dose combination is additive or synergistic compared to that provided by the corresponding ralinepag, riociguat, treprostinil, and / or iloprost monotherapies.

A method in which: (a) a patient is positioned in an X-ray device; (b) a 3D scout image with reduced dose and with a predefined volume size and a predefined center of rotation is created; (c) on the 3D scout image, a practitioner marks the tooth (d) a software determines, based on the position of the enveloping geometry, the available centers of rotation and calculates, based on reference points of the enveloping geometry, the imaging positions; (e) based on the imaging positions, a center of rotation is selected; (f) the previously determined aperture positions and the detector regions to be irradiated are transmitted; (g) the high-resolution image is reconstructed and the newly acquired high-resolution information is superimposed in the 3D scout image; (h) the practitioner receives the 3D scout image for diagnosis and further use.

This invention discloses an adhesive tissue equivalent compensation membrane for breast cancer radiotherapy, relating to the field of radiotherapy compensation membrane technology. It includes: an adhesive layer on one side that directly contacts the skin; a variable tissue equivalent layer; and an outer protective layer for providing mechanical protection while also ensuring compatibility with radiotherapy equipment. The proposed zoned adjustable microchannel / microcavity filling mechanism can locally adjust the relative electron density and water equivalent according to the radiation path, thereby achieving point-to-point spatial matching with the equivalent tissue thickness required by the radiotherapy plan. This mechanism fundamentally reduces dose perturbations caused by surface geometry irregularities or tissue inhomogeneities, allowing for more reliable reproduction of the dose distribution in the treatment plan during actual irradiation, and reducing the risk of underdose or overdose in near-surface and interface regions.

The invention discloses an error correction method based on a multi-leaf collimator, and relates to the technical field of radiotherapy, and the error correction method based on the multi-leaf collimator comprises the following steps: an error modeling step: collecting position images of the multi-leaf collimator at different rack angles through an electron radiation field imaging device, calculating an error value between an actual position and an ideal position of the blade of the multi-blade collimator based on the position image, and constructing an error function model delta x = f (G, N, X) taking a rack angle G, a blade serial number N and a blade position X as independent variables; a plan correction step: obtaining a multi-leaf collimator motion sequence and a rack angle sequence of the treatment plan; and calling the error function model, and calculating a prediction error delta x for each multi-leaf collimator leaf under each control point in the treatment plan. The error correction method based on the multi-leaf collimator is used for improving the calculation precision of the radiotherapy dose and reducing the dose deviation caused by the system error of the multi-leaf collimator from the source. The invention further discloses an error correction system based on the multi-leaf collimator, a storage medium and an error correction device based on the multi-leaf collimator.